Cited by 139Treatment of Major DepressionPharmacogenetics and Drug MetabolismPharmaceutical studies and practices

The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.

Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression

Open access

Zhao, Xiaochen, Venkata, Swarajya Lakshmi Vattem, Moaddel, Ruin, Luckenbaugh, Dave A., Brutsche, Nancy E., Ibrahim, Lobna, Zarate Jr, Carlos A., Mager, Donald E., Wainer, Irving W.·2012·British Journal of Clinical Pharmacology

DOI 10.1111/j.1365-2125.2012.04198.xPMC PMC3630750

Open this paper in CoChat — free account Open PDF

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • (R,S)‐ketamine is a phencyclidine derivative that was initially developed as an anaesthetic agent and which is currently being studied in the treatment of pain and depression. After administration, the drug is extensively N‐demethylated to (R,S)‐norketamine. The pharmacokinetics of ketamine and norketamine have been extensively studied in volunteers and patients after the administration of anaesthetic and sub‐anaesthetic doses. However, ketamine and norketamine are extensively transformed into a series of diastereomeric hydroxyketamines and hydroxynorketamines and (R,S)‐dehydronorketamine metabolites. The plasma kinetics of these metabolites have not been elucidated. WHAT THIS STUDY ADDS • The current study expands the characterization of the disposition kinetics of (R,S)‐ketamine and (R,S)‐norketamine and presents a population pharmacokinetic analysis of (R)‐ketamine, (S)‐ketamine, (R)‐norketamine, (S)‐norketamine, (R)‐dehydronorketamine, (S)‐ dehydronorketamine and (2S,6S;2R,6R)‐hydroxynorketamine and the serum concentration–time profiles of multiple ketamine metabolites observed in the plasma of patients after a single 40 min infusion of a sub‐anaesthetic dose of the drug. The data demonstrate that while norketamine is an initial metabolite, it is not the major circulating metabolite and suggest that the determination of the downstream metabolites of ketamine may play a role in the pharmacological effects of the drug. AIM To construct a population pharmacokinetic (popPK) model for ketamine (Ket), norketamine (norKet), dehydronorketamine (DHNK), hydroxynorketamine (2S,6S;2R,6R)‐HNK) and hydroxyketamine (HK) in patients with treatment‐resistant bipolar depression. METHOD Plasma samples were collected at 40, 80, 110, 230 min on day 1, 2 and 3 in nine patients following a 40 min infusion of (R,S)‐Ket (0.5 mg kg−1) and analyzed for Ket, norKet and DHNK enantiomers and (2S,6S;2R,6R)‐HNK, (2S,6S;2R,6R)‐HK and (2S,6R;2R,6S)‐HK. A compartmental popPK model was constructed that included all quantified analytes, and unknown parameters were estimated with an iterative two‐stage algorithm in ADAPT5. RESULTS Ket, norKet, DHNK and (2S,6S;2R,6R)‐HNK were present during the first 230 min post infusion and significant concentrations (>5 ng ml−1) were observed on day 1. Plasma concentrations of (2S,6S;2R,6R)‐HK and (2S,6R;2R,6S)‐HK were below the limit of quantification. The average (S) : (R) plasma concentrations for Ket and DHNK were <1.0 while no significant enantioselectivity was observed for norKet. There were large inter‐patient variations in terminal half‐lives and relative metabolite concentrations; at 230 min (R,S)‐DHNK was the major metabolite in four out of nine patients, (R,S)‐norKet in three out of nine patients and (2S,6S;2R,6R)‐HNK in two out of nine patients. The final PK model included three compartments for (R,S)‐Ket, two compartments for (R,S)‐norKet and single compartments for DHNK and HNK. All PK profiles were well described, and parameters for (R,S)‐Ket and (R,S)‐norKet were in agreement with prior estimates. CONCLUSION This represents the first PK analysis of (2S,6S;2R,6R)‐HNK and (R,S)‐DHNK. The results demonstrate that while norKet is the initial metabolite, it is not the main metabolite suggesting that future Ket studies should include the analysis of the major metabolites.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2012.04198.x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citation
A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citation
Ketamine
Kohrs, R., & Durieux, M. E. (1998) · Anesthesia & Analgesia · doi:10.1097/00000539-199811000-00039 · Cited by 635
Rapid Resolution of Suicidal Ideation After a Single Infusion of an N -Methyl- D -Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Self-citation
Taming the Ketamine Tiger
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
Intraoperative Ketamine Reduces Perioperative Opiate Consumption in Opiate-dependent Patients with Chronic Back Pain Undergoing Back Surgery
Loftus, R. W., Yeager, M. P., Clark, J. A., Brown, J. R., Abdu, W. A., Sengupta, D. K., & Beach, M. L. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181e90914 · Cited by 471
Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1
Sigtermans, M. J., van Hilten, J. J., Bauer, M. C. R., Arbous, M. S., Marinus, J., Sarton, E. Y., & Dahan, A. (2009) · Pain · doi:10.1016/j.pain.2009.06.023 · Cited by 471
The use of ketamine in complex regional pain syndrome: possible mechanisms
Schwartzman, R. J., Alexander, G. M., & Grothusen, J. R. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.31 · Cited by 225
Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers
Yanagihara, Y., Ohtani, M., Kariya, S., Uchino, K., Hiraishi, T., Ashizawa, N., Aoyama, T., Yamamura, Y., Yamada, Y., & Iga, T. (2002) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.336 · Cited by 219
Pharmacokinetics of ketamine in man.
Wieber, J., Gugler, R., Hengstmann, J. H., & Dengler, H. J. (1975) · PubMed · Cited by 176

Show all 32 references

Research works printed but not linked: 2

Trevor AJ, 1983, Stereoselective Metabolism of Ketamine Enantiomers, Phencyclidine and Related Arylcyclohexylamines: Present and Future Applications, 279
10.1016/S0009-9236(01)06321-4 · DOI

Sorted by citations

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citation
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Self-citation
Ketamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254
Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression
Su, T., Chen, M., Li, C., Lin, W.-C., Hong, C., Gueorguieva, R. V., Tu, P., Bai, Y., Cheng, C., & Krystal, J. H. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.94 · Cited by 211
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS
Abdallah, C. G., Adams, T. G., Kelmendi, B., Esterlis, I., Sanacora, G., & Krystal, J. H. (2016) · Depression and Anxiety · doi:10.1002/da.22501 · Cited by 206
Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors
Moaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.023 · Cited by 176
Self-citation
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling
Cavalleri, L., Merlo Pich, E., Millan, M. J., Chiamulera, C., Kunath, T., Spano, P. F., & Collo, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.241 · Cited by 156
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
Kohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 155
A brief history of antidepressant drug development: from tricyclics to beyond ketamine
Pereira, V. S., & Sato, V. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.39 · Cited by 135
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 131
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
(R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function
Paul, R. K., Singh, N. S., Khadeer, M., Moaddel, R., Sanghvi, M., Green, C. E., O’Loughlin, K., Torjman, M. C., Bernier, M., & Wainer, I. W. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000285 · Cited by 115
Self-citation
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur
Swainson, J., McGirr, A., Blier, P., Brietzke, E. M., Richard‐Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., et al. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970860 · Cited by 124
Stereoselective and regiospecific hydroxylation of ketamine and norketamine
Desta, Z., Moaddel, R., Ogburn, E. T., Xu, C., Ramamoorthy, A., Venkata, S. L. V., Sanghvi, M., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2012) · Xenobiotica · doi:10.3109/00498254.2012.685777 · Cited by 114
Self-citation
Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine
Shirayama, Y., & Hashimoto, K. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx108 · Cited by 113
Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing
Fanta, S., Kinnunen, M., Backman, J. T., & Kalso, E. A. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1826-y · Cited by 109
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000149 · Cited by 92
Self-citation
Ketamine and other potential glutamate antidepressants
Dutta, A., McKie, S., & Deakin, J. F. W. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.10.028 · Cited by 92
Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression
du Jardin, K. G., Liebenberg, N., Müller, H. K., Elfving, B., Sánchez, C., & Wegener, G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4327-5 · Cited by 88
Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor
Sałat, K., Siwek, A., Starowicz, G., Librowski, T., Nowak, G., Drabik, U., Gajdosz, R., & Popik, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.037 · Cited by 77
Experimental medication treatment approaches for depression
Ionescu, D., & Papakostas, G. I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.33 · Cited by 79
Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis
Kamp, J., Jonkman, K., van Velzen, M., Aarts, L. P. H. J., Niesters, M., Dahan, A., & Olofsen, E. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.06.067 · Cited by 76
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 78
Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress
Rincón‐Cortés, M., & Grace, A. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112367 · Cited by 72
A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response‐related difference in mitochondrial networks
Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M. P., Laje, G., Zarate, C., Barbas, C., & Wainer, I. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12494 · Cited by 71
Self-citation
Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature
Kamp, J., van Velzen, M., Olofsen, E., Boon, M., Dahan, A., & Niesters, M. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1689958 · Cited by 70
Ketamine and its metabolites: Potential as novel treatments for depression
Zhang, K., Yao, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109305 · Cited by 69
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 73
Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5‐year study of 51 patients
Marchetti, F., Coutaux, A., Bellanger, A., Magneux, C., Bourgeois, P., & Mion, G. (2014) · European Journal of Pain · doi:10.1002/ejp.624 · Cited by 68
Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance
Rao, L. K., Flaker, A. M., Friedel, C. C., & Kharasch, E. D. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001392 · Cited by 67
Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex
Woelfer, M., Li, M., Colic, L., Liebe, T., Di, X., Biswal, B., Murrough, J., Lessmann, V., Brigadski, T., & Walter, M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1679391 · Cited by 64
Metaplastic Effects of Subanesthetic Ketamine on CA1 Hippocampal Function
Izumi, Y., & Zorumski, C. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.002 · Cited by 63
Drug Pharmacokinetics Determined by Real‐Time Analysis of Mouse Breath
Li, X., Sinues, P., Dallmann, R., Bregy, L., Hollmén, M., Proulx, S. T., Brown, S. A., Detmar, M. J., Kohler, M., & Zenobi, R. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201503312 · Cited by 62
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects
Li, M., Woelfer, M., Čolić, L., Safron, A., Chang, C. E., Heinze, H., Speck, O., Mayberg, H. S., Biswal, B. B., Salvadore, G., et al. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0942-y · Cited by 57
Quantitative chiral and achiral determination of ketamine and its metabolites by LC–MS/MS in human serum, urine and fecal samples
Hasan, M., Hofstetter, R. K., Fassauer, G. M., Link, A., Siegmund, W., & Oswald, S. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.02.035 · Cited by 55
Ketamine Pharmacokinetics
Kamp, J., Olofsen, E., Henthorn, T. K., van Velzen, M., Niesters, M., Dahan, A., & for the Ketamine Pharmacokinetic Study Group (2020) · Anesthesiology · doi:10.1097/aln.0000000000003577 · Cited by 55
Pharmacotherapy
Feeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 57
The role of eEF2 kinase in the rapid antidepressant actions of ketamine
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.005 · Cited by 52
Ketamine and Active Ketamine Metabolites Regulate STAT3 and the Type I Interferon Pathway in Human Microglia: Molecular Mechanisms Linked to the Antidepressant Effects of Ketamine
Ho, M., Zhang, C., Zhang, L., Li, H., & Weinshilboum, R. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01302 · Cited by 50
Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression
Ho, M.-F., Correia, C., Ingle, J. N., Kaddurah-Daouk, R., Wang, L., Kaufmann, S. H., & Weinshilboum, R. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.032 · Cited by 49
The neurophysiology of ketamine: an integrative review
McMillan, R. L., & Muthukumaraswamy, S. D. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0090 · Cited by 51
Analgesic Response to Intravenous Ketamine Is Linked to a Circulating microRNA Signature in Female Patients With Complex Regional Pain Syndrome
Douglas, S. R., Shenoda, B. B., Qureshi, R., Saçan, A., Alexander, G. M., Perreault, M. J., Barrett, J. E., Aradillas, E., Schwartzman, R. J., & Ajit, S. K. (2015) · Journal of Pain · doi:10.1016/j.jpain.2015.05.008 · Cited by 47
Effect of Ketamine on Limbic GABA and Glutamate: A Human In Vivo Multivoxel Magnetic Resonance Spectroscopy Study
Silberbauer, L., Spurny‐Dworak, B., Handschuh, P. A., Klöbl, M., Bednařík, P., Reiter, B., Ritter, V., Trost, P., Konadu, M. E., Windpassinger, M., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.549903 · Cited by 46
Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition
Lüscher, B., Feng, M., & Jefferson, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.03.002 · Cited by 41
Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant ‐ implications for precision dosing in a global perspective
Langmia, I. M., Just, K. S., Yamoune, S., Müller, J. P., & Stingl, J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15467 · Cited by 41
A meta-analysis of the effects of ketamine on suicidal ideation in depression patients
Shen, Z., Gao, D., Lv, X., Wang, H., & Yue, W. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02973-1 · Cited by 41
The distribution and clearance of (2S,6S)‐hydroxynorketamine, an active ketamine metabolite, in Wistar rats
Moaddel, R., Sanghvi, M., Dossou, K. S. S., Ramamoorthy, A., Green, C., Bupp, J. E., Swezey, R. R., O’Loughlin, K. G., & Wainer, I. W. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.157 · Cited by 41
Self-citation
Dose-response characteristics of intravenous ketamine on dissociative stereotypy, locomotion, sensorimotor gating, and nociception in male Sprague-Dawley rats
Radford, K. D., Park, T. Y., Lee, B. H., Moran, S., Osborne, L. A., & Choi, K. H. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.12.014 · Cited by 41
(2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans
Collo, G., Cavalleri, L., Chiamulera, C., & Pich, E. M. (2018) · Neuroreport · doi:10.1097/wnr.0000000000001131 · Cited by 40
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2 R ,6 R )‐Hydroxynorketamine in Healthy Volunteers
Raja, S. M., Guptill, J. T., Mack, M., Peterson, M., Byard, S. J., Twieg, R. J., Jordan, L., Rich, N., Castledine, R. A., Bourne, S. L., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3391 · Cited by 38
Self-citation
The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug
Pałucha-Poniewiera, A. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.02.011 · Cited by 36
Inhibition of the l-arginine–nitric oxide pathway mediates the antidepressant effects of ketamine in rats in the forced swimming test
Zhang, G.-F., Wang, N., Shi, J., Shixia, X., Li, X., Ji, M., Zuo, Z., Zhou, Z., & Yang, J. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.05.010 · Cited by 36
The modulation of BDNF expression and signalling dissects the antidepressant from the reinforcing properties of ketamine: Effects of single infusion vs. chronic self-administration in rats
Caffino, L., Chio, M. D., Giannotti, G., Vènniro, M., Mutti, A., Padovani, L., Cheung, D., Fumagalli, G. F., Yew, D. T. W., Fumagalli, F., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.014 · Cited by 36
Sex-dependent metabolism of ketamine and ( 2R,6R )-hydroxynorketamine in mice and humans
Highland, J. N., Farmer, C., Zanos, P., Lovett, J., Zarate, C. A., Moaddel, R., & Gould, T. D. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211064922 · Cited by 36
Self-citation
Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography
Spies, M., James, G. M., Berroterán-Infante, N., Ibeschitz, H., Kranz, G. S., Unterholzner, J., Godbersen, M., Gryglewski, G., Hienert, M., Jungwirth, J., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx085 · Cited by 34
Ketamine – A New Antidepressant Drug with Anti-Inflammatory Properties
Jóźwiak-Bębenista, M., Sokołowska, P., Wiktorowska‐Owczarek, A., Kowalczyk, E., & Sienkiewicz, M. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001823 · Cited by 33
A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex
du Jardin, K. G., Müller, H. K., Sánchez, C., Wegener, G., & Elfving, B. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.05.029 · Cited by 31
Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration–Time Curve to the Minimum Inhibitory Concentration ≥400 Target
Bhongsatiern, J., Stockmann, C. R., Roberts, J. K., Tian, Y., Korgenski, K. E., Spigarelli, M. G., Desai, P. B., & Sherwin, C. M. T. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000216 · Cited by 31
Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment‐Refractory Depression
Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K. A., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2640 · Cited by 30
Enantioselective pharmacokinetics of (R)‐ and (S)‐ketamine after a 5‐day infusion in patients with complex regional pain syndrome
Goldberg, M. E., Torjman, M. C., Schwartzman, R. J., Mager, D. E., & Wainer, I. W. (2010) · Chirality · doi:10.1002/chir.20890 · Cited by 30
Self-citation
Pharmacokinetics of ketamine and three metabolites in Beagle dogs under sevoflurane vs. medetomidine comedication assessed by enantioselective capillary electrophoresis
Sandbaumhüter, F. A., Theurillat, R., Bektas, R. N., Kutter, A. P. N., Bettschart‐Wolfensberger, R., & Thormann, W. (2016) · Journal of Chromatography A · doi:10.1016/j.chroma.2016.07.060 · Cited by 27
Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines
Highland, J. N., Morris, P. J., Konrath, K. M., Riggs, L. M., Hagen, N. R., Zanos, P., Powels, C. F., Moaddel, R., Thomas, C. J., Wang, A. Q., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00761 · Cited by 28
Self-citation
Effects of medetomidine and its active enantiomer dexmedetomidine on N‐demethylation of ketamine in canines determined in vitro using enantioselective capillary electrophoresis
Sandbaumhüter, F. A., Theurillat, R., & Thormann, W. (2015) · Electrophoresis · doi:10.1002/elps.201500147 · Cited by 27
Acetylcholine and metacognition during sleep
Gott, J. A., Stücker, S., Kanske, P., Haaker, J., & Dresler, M. (2024) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103608 · Cited by 25
The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression
McDonnell, C., Dunphy-Doherty, F., Rouine, J., Bianchi, M., Upton, N., Sokolowska, E., & Prenderville, J. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.599588 · Cited by 23
Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks
Spies, M., Klöbl, M., Höflich, A. S., Hummer, A., Vanicek, T., Michenthaler, P., Kranz, G. S., Hahn, A., Winkler, D., Windischberger, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46702-x · Cited by 22
Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
Clinical and pharmacokinetic evaluation of S-ketamine for intravenous general anaesthesia in horses undergoing field castration
Casoni, D. C., Spadavecchia, C., Wampfler, B., Thormann, W., & Levionnois, O. (2015) · Acta veterinaria Scandinavica · doi:10.1186/s13028-015-0112-4 · Cited by 21
Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine’s Antidepressant Action
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2017) · Chronic Stress · doi:10.1177/2470547017743511 · Cited by 23
Ketamine as Potential Treatment for Postpartum Depression: A Narrative Review
Chen-Li, D. C. J., Lui, L. M. W., Rosenblat, J. D., Lipsitz, O., Teopiz, K. M., Ho, R., Vinberg, M., Golts, M., Jawad, M. Y., Lee, Y. L., et al. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0082 · Cited by 20
Enantioselective CE–MS analysis of ketamine metabolites in urine
Sandbaumhüter, F. A., Aerts, J. T., Theurillat, R., Andrén, P. E., Thormann, W., & Jansson, E. T. (2022) · Electrophoresis · doi:10.1002/elps.202200175 · Cited by 20
Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(–) Ketamine Concentrations
Henthorn, T. K., Avram, M. J., Dahan, A., Gustafsson, L. L., Persson, J., Krejcie, T. C., & Olofsen, E. (2018) · Anesthesiology · doi:10.1097/aln.0000000000002265 · Cited by 20
Dextromethorphan and memantine after ketamine analgesia: a randomized control trial
Martin, E., Sorel, M., Morel, V., Marcaillou, F., Picard, P., Delage, N., Tiberghien-Chatelain, F., Crosmary, M.-C., Najjar, M., Colamarino, R., et al. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s207350 · Cited by 18
Rapid-Acting Antidepressants
Kadriu, B., Subramanian, S., Deng, Z., Henter, I. D., Park, L. T., & Zarate, C. A. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190929565.003.0013 · Cited by 18
Serotonergic transmission plays differentiated roles in the rapid and sustained antidepressant‐like effects of ketamine
Yin, Y., Yan, J., Wei, Q., Sun, S., Ding, Y., Zhang, L., & Li, Y. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17324 · Cited by 20
Prediction of human efficacious antidepressant doses using the mouse forced swim test
Yuen, E., Swanson, S., & Witkin, J. M. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.09.002 · Cited by 18
Targeted mass spectrometry of ketamine and its metabolites cis-6-hydroxynorketamine and norketamine in human blood serum
Kurzweil, L., Danyeli, L. V., Şen, Z. D., Fejtová, A., Walter, M., & Gensberger‐Reigl, S. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122214 · Cited by 17
Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats
Moaddel, R., Sanghvi, M., Ramamoorthy, A., Jóźwiak, K., Singh, N., Green, C., O’Loughlin, K. G., Torjman, M. C., & Wainer, I. W. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.03.030 · Cited by 17
Self-citation
Association of the delayed changes in glutamate levels and functional connectivity with the immediate network effects of S-ketamine
Danyeli, L. V., Şen, Z. D., Čolić, L., Kurzweil, L., Gensberger‐Reigl, S., Macharadze, T., Götting, F. N., Refisch, A., Liebe, T., Chand, T., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02346-0 · Cited by 16
Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis via Inhibiting the Production of Neurotoxic Metabolites of the Kynurenine Pathway
Mandal, G., Kirkpatrick, M., Alboni, S., Mariani, N., Pariante, C. M., & Borsini, A. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae041 · Cited by 15
“Ketamine enantiomers were selected to fall within the range of concentrations observed in the plasma of depressed patients after ketamine infusion therapy (Zarate et al., 2012; Zhao et al., 2012).”
A PK–PD model of ketamine-induced high-frequency oscillations
Flores, F. J., Ching, S., Hartnack, K. E., Fath, A. B., Purdon, P. L., Wilson, M. A., & Brown, E. N. (2015) · Journal of Neural Engineering · doi:10.1088/1741-2560/12/5/056006 · Cited by 16
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Molecular Mechanism and Clinical Relevance of Ketamine as Rapid‐Acting Antidepressant
Pešić, V., Petrović, J., & Jukić, M. M. (2016) · Drug Development Research · doi:10.1002/ddr.21335 · Cited by 15
Separation of hydroxynorketamine stereoisomers using capillary electrophoresis with sulfated β‐cyclodextrin and highly sulfated γ‐cyclodextrin
Sandbaumhüter, F. A., Theurillat, R., & Thormann, W. (2017) · Electrophoresis · doi:10.1002/elps.201700016 · Cited by 17
Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion
Moaddel, R., Farmer, C., Yavi, M., Kadriu, B., Zhu, M., Fan, J., Chen, Q., Lehrmann, E., Fantoni, G., De, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108527 · Cited by 14
Self-citation
Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged‐Release Ketamine With Emphasis on 2,6‐Hydroxynorketamines
Weiss, M., & Siegmund, W. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.993 · Cited by 13
Stereochemical and structural effects of (2R,6R)-hydroxynorketamine on the mitochondrial metabolome in PC-12 cells
Faccio, A. T., Rupérez, F. J., Singh, N., Angulo, S., Tavares, M. F. M., Bernier, M., Barbas, C., & Wainer, I. W. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.03.008 · Cited by 13
Self-citation
Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects
Hasan, M., Modeß, C., Roustom, T., Dokter, A., Grube, M., Link, A., Rey, H., Adler, S., Meissner, K., & Siegmund, W. (2021) · Anesthesiology · doi:10.1097/aln.0000000000003829 · Cited by 13
High Yielding Continuous-Flow Synthesis of Norketamine
Veguillas, M., Moore, J. C., Howie, R. A., Castledine, R. A., Bourne, S. L., Jenkins, G. N., Licence, P., Poliakoff, M., & George, M. W. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00407 · Cited by 13
NMDA Antagonists for Treatment-Resistant Depression
Farber, N. B. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_165 · Cited by 14
General Anesthetics: Aspects of Chirality, Pharmacodynamics, and Pharmacokinetics
Cizmáriková, R., Habala, L., & Valentová, J. (2025) · Pharmaceuticals · doi:10.3390/ph18020250 · Cited by 14
Perioperative ketamine for acute analgesia and beyond.
Porter, S. B. (2019) · PubMed Central · doi:10.2478/rjaic-2019-0010 · Cited by 11
Antidepressants enter cells, organelles, and membranes
Blumenfeld, Z., Bera, K., Ċastrén, E., & Lester, H. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01725-x · Cited by 10

Authors: Zhao, X., Venkata, S. L. V., Moaddel, R., Luckenbaugh, D. A., Brutsche, N. E., Ibrahim, L., Zarate Jr, C. A., Mager, D. E., & Wainer, I. W.
Affiliations: University at Buffalo, State University of New York (US)
National Institute on Aging (US)
National Institutes of Health (US)
Corresponding author: Wainer, Irving W.
ORCID: Zhao, Xiaochen
Moaddel, Ruin
Mager, Donald E.
Wainer, Irving W.
Venue: British Journal of Clinical Pharmacology
Publisher: Wiley
Published: 2012-07-10
Volume: 74
Issue: 2
Pages: 304-314
ISSN: 0306-5251 (ISSN-L)
1365-2125
DOI: 10.1111/j.1365-2125.2012.04198.x
PMC: PMC3630750
OpenAlex: W2158336114
Cited by: 137
References: 32
Citations by year: 2026: 4 · 2025: 10 · 2024: 10 · 2023: 12 · 2022: 12 · 2021: 12 · 2020: 8 · 2019: 10 · 2018: 12 · 2017: 11 · 2016: 11 · 2015: 14 · 2014: 5 · 2013: 1 · 2012: 3
FWCI: 5.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: British Journal of Clinical Pharmacology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Institute of General Medical Sciences (GM 57980, R01GM057980)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords: ketamine, norketamine, dehydronorketamine, hydroxynorketamine, ketamine metabolites, population pharmacokinetic model, treatment-resistant bipolar depression, enantiomers, N-demethylation, plasma concentration-time curve, drug disposition kinetics
MeSH terms: Adult, Algorithms, Antidepressive Agents, Biotransformation, Bipolar Disorder, Double-Blind Method, Drug Resistance, Female, Humans, Hydroxylation, Infusions, Parenteral, Ketamine, Male, Middle Aged, Models, Biological, Cross-Over Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks